Commack: 
Congratulations Dr. Weber and the Island retina team for FDA approval of the Lucerne study - A new eye treatment called Vabysmo
Regeneron
(Photon Study)
New Treatment for Diabetic Macular Edema
Enrollment is Closed
About this Study
A randomized, double-masked, active-controlled phase 2/3 study of the efficacy and safety of high-dose aflibercept in patients with diabetic macular edema.
This study is using a higher concentration of Eylea with the hope that patients will need injections much less frequently, hopefully, every 3-4 months and still maintain visual improvements.
Genentech Lucerne Study
Enrollment is Closed
Congratulations Dr. Weber and the Island retina team for FDA approval of the Lucerne study - A new eye treatment called Vabysmo, this drug is approved for the treatment of wet AMD and Diabetic Macular Edema.
Opthea
(Coast Study)
New Treatment for Neovascular Age-Related Macular Degeneration
Enrollment is Open
About this Study
This is a phase 3 study looking at adding a new molecule in addition to Lucentis or Eylea. It is hoped that patients will have better results and less frequent treatment.
New Treatment for Neovascular Age-Related Macular Degeneration
Enrollment is Open
About this Study
This is a phase 2 study looking at a along-acting intraocular drug called vorolanib in patients previously treated for wet AMD.
It is hoped that this new drug will control the disease and reduce the need for frequent injections.
DRCR Retina Network
Fenofibrate for the treatment of diabetic retinopathy
Enrollment is Open
About this Study
This is a phase 3 study looking at a new oral treatment (pill) to prevent progression of diabetic eye disease and the need for laser and/or injections.
Oculis DX 219
New Treatment for diabetic macular edema using an eye drop
Enrollment is open
About this Study
Phase 2/3 study looking at an eye drop to treat diabetic macular edema.
